Search This Board: 
Created: 09/21/2015 08:51:43 AM - Followers: 10 - Board type: Free - Posts Today: 0

Akari is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, and leukotriene system,
for the treatment of rare and orphan diseases with unmet need. We believe that blocking early mediators of inflammation
will prevent initiation and continual amplification of the processes that cause certain diseases.

Nomacopan is a recombinant small protein (16,740 Da) that acts on complement component-C5,
preventing release of C5a and formation of C5b–9 (also known as the membrane attack complex, or MAC),
and independently also inhibits leukotriene B4, or LTB4, activity, both elements that are co-located as part of the immune/inflammatory response.

Nomacopan is currently being clinically evaluated in four indications:

  • bullous pemphigoid (BP), , a severe blistering skin disease
    atopic keratoconjunctivitis (AKC), a sight threatening surface of the eye condition
    thrombotic microangiopathys (TMA) including including atypical hemolytic uremic syndrome (aHUS) and hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT TMA)
    paroxysmal nocturnal hemoglobinuria (PNH).

Akari believes that the dual action of nomacopan on both C5 and LTB4 may be beneficial in AKC, BP, and aHUS. Akari is also developing other tick derived proteins, including longer acting versions.

Nomacopan is a highly soluble and stable biological molecule, and independently binds to both C5 and LTB4.  This novel dual binding enables targeting of two distinct and separate disease categories based on their underlying etiology.

Four Primary/Lead Indications in Phase II/III Plus Pipeline of Earlier-Stage Targets


Akari Therapeutics Announces Appointment of Chief Financial Officer

July 1, 2020

Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC

July 1, 2020


June 1, 2020

Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients

May 1, 2020

Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

March 31, 2020

Patients with COVID-19 pneumonia

  • The Company believes nomacopan’s dual inhibition of both the complement (C5) and leukotriene (LTB4) pathways makes
    the drug potentially well suited for the treatment of patients with COVID-19 pneumonia and related COVID disease.
    Leukotriene inhibition is a validated pathway for the treatment of severe lung inflammation and LTB4 is a potent granulocyte and
    leukocyte attractant which in turn are key drivers of the damaging cytokine storm that underpins acute respiratory distress syndrome (ARDS).
    Likewise, there is growing evidence of the role of the complement pathway in the microthrombi and organ damage associated with COVID-19 pneumonia.
    In pre-clinical lung inflammation models including a study of viral induced lung inflammation, nomacopan (formerly known as Coversin)
    showed significant reductions in key lung inflammatory markers such as neutrophils and lung vascular leakage (Garcia et al., 2013; Roversi et al., 2013).
    Likewise in sepsis models (Huber-Lang et al., 2014) nomacopan has shown significant downregulation of a wide range of pro-inflammatory cytokines
    and chemokines including TNF, IL-6, GM-CSF, IL1alpha, IL1beta, IL17, MCP1 (CCL2), MIP1alpha (CCL3),
    MIP1beta (CCL4) which have all been shown to be elevated in patients with COVID-19 disease.
    Akari is actively pursuing several clinical study opportunities in patients with COVID-19 pneumonia in the UK and U.S.
    The Company intends to provide additional detail when these programs are finalized and approved.


 *DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
Akari Therapeutcis (AKTX) Presesnts Positive Results from Two conix 05/09/2022 06:23:44 PM
#545 $AZN buyout of $ALXN. $AKTX MotionOffense78 12/12/2020 03:04:44 PM
#544 $AKTX added. MotionOffense78 11/09/2020 01:39:08 PM
#543 Lmao. Clueless Rogerthat1 09/05/2020 03:49:12 PM
#542 Completely doomed company. Nobody touching it! More vol candeloro 08/31/2020 02:27:40 PM
#541 Funny to read the messages from 2 years candeloro 08/27/2020 04:05:44 PM
#540 yeah, pretty awful. candeloro 08/27/2020 03:55:05 PM
#539 Akari Therapeutics P (AKTX) mick 08/27/2020 03:50:52 PM
#538 mick, old pump and dumper. Now 10% lower. candeloro 08/27/2020 03:46:38 PM
#537 $AKTX Akari Therapeutics P (AKTX) mick 08/08/2020 05:45:33 PM
#536 $AKTX BIG TIME MOVE mick 08/08/2020 05:45:17 PM
#535 Added a bunch Friday $AKTX. Have bigly position Rogerthat1 08/08/2020 05:24:12 PM
#534 $AKTX Akari Therapeutics PLC (NASDAQ: AKTX): interim update mick 08/05/2020 10:39:45 AM
#533 $AKTX going to be huge runner my friend !!!!! mick 07/29/2020 09:40:55 PM
#532 $AKTX i am looking fer $8 plus !!!!! mick 07/29/2020 09:38:27 PM
#531 $AKTX why not this wk ????? biotech are mick 07/29/2020 09:36:54 PM
#530 $AKTX Akari Therapeutics P (AKTX) mick 07/29/2020 09:33:53 PM
#529 $AKTX I AGREE WITH PPS , EXCELLENT mick 07/29/2020 09:33:37 PM
#528 Agreed. And I'm watching $AKTX for signs to Ablivious 07/29/2020 09:55:10 AM
#527 Excellent to see some new posters here. Give BrazenBull 07/29/2020 01:09:01 AM
#526 $AKTX here you have Akari’s medical director as Rogerthat1 07/28/2020 12:37:10 AM
#525 I was buying $capr at 90¢ and been Rogerthat1 07/27/2020 10:01:12 PM
#524 $AKTX YOU ARE WELCOME. AKTX Bid: 2.08 Ask: mick 07/27/2020 05:05:00 PM
#523 Thanks for the post Mick. We are gold MotionOffense78 07/27/2020 04:55:30 PM
#522 $AKTX Akari Therapeutics (AKTX) $5 target !!!!! mick 07/27/2020 12:51:53 PM
#521 $AKTX reading your theory mick 07/25/2020 08:34:48 PM
#520 $AKTX READING YOUR DD, outstanding stuff !!!!! mick 07/25/2020 08:33:04 PM
#519 $AKTX mick 07/25/2020 08:31:25 PM
#518 $AKTX i didn't look @ a.h. finished up !!!!! mick 07/25/2020 08:30:45 PM
#517 $AKTX, i will try fer more shares !!!!! mick 07/25/2020 08:29:25 PM
#516 She ready to go for a run imo Rogerthat1 07/25/2020 08:24:52 PM
#515 $AKTX THANX FOR UPDATING. how ya like 5yr. mick 07/25/2020 08:20:58 PM
#514 $AKTX GOOD REPORE' mick 07/25/2020 08:09:32 PM
#513 Last year had the same pattern. Did a Rogerthat1 07/25/2020 08:02:53 PM
#512 $AKTX FIVE YR. mick 07/25/2020 07:59:34 PM
#511 $AKTX, I THINK $7 TO $10 PPS MY FRIEND mick 07/25/2020 07:57:05 PM
#510 I’ve posted a lot of $AKTX DD on Rogerthat1 07/25/2020 06:47:08 PM
#509 $AKTX Akari Therapeutics P (AKTX) mick 07/25/2020 02:18:23 PM
#508 $AKTX “We remain focused on our mission of mick 07/24/2020 11:28:50 AM
#507 $AKTX ]fast track approval Open pivotal study in mick 07/24/2020 11:25:58 AM
#506 $AKTX 1.9700 -0.0300 -1.50% USD 11:20AM EDT 55.152k mick 07/24/2020 11:23:35 AM
#505 $AKTX DID YA SEE DIS TRADE ????? ANYONE mick 07/21/2020 04:18:37 PM
#504 $AKTX The latest on the coronavirus pandemic mick 07/21/2020 02:15:33 PM
#503 $AKTX STRONG BUY !!!!! mick 07/21/2020 01:45:33 PM
#502 $AKTX Price To Book 37.96 Price to Tangible mick 07/21/2020 01:35:06 PM
#501 $AKTX [-chart] mick 07/21/2020 12:56:35 PM
#500 $AKTX INDEED , i updated ibox mick 07/21/2020 12:15:04 PM
#499 $AKTX a steal at the current pps. Lots MotionOffense78 07/21/2020 12:04:08 PM
#498 $AKTX NEW YORK and LONDON, May 29, 2020 mick 07/21/2020 11:41:11 AM
#497 $AKTX ]Open pivotal study in pediatric hematopoietic stem mick 07/21/2020 11:06:44 AM
Post Subject